Eisai Co., Ltd.

4523

JP3160400002

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:30:00 2025-06-23 am EDT			5-day change	1st Jan Change
3,951.00 ^JPY	+0.18%		-2.54%	-8.73%

Jun. 04	Trump's tariffs and threatened trade actions	RE
Jun. 04	Trump's tariffs and threatened trade actions	RE

Eisai, Biogen to Shift Some Lecanemab Ingredient Production to US Amid Tariff Concerns

Published on 05/15/2025 at 08:50

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Eisai Co., Ltd.

Trump's tariffs and threatened trade actions	Jun. 04	RE
Trump's tariffs and threatened trade actions	Jun. 04	RE
Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection	Jun. 04	MT
Trump's tariffs and threatened trade actions	May. 30	RE
Jefferies Adjusts Eisai's Price Target to 4,200 Yen From 3,600 Yen, Keeps at Hold	May. 30	MT
Japan's Nikkei falls as court battle over US tariffs weighs	May. 29	RE
Trump's tariffs and threatened trade actions	May. 28	RE
Eisai Co Ltd - Obtain Favorable Decision In Patent Infringement Litigation Related To Lenvatinib In The U.S.	May. 28	RE
Angle shares fall on weak 2025 outlook despite narrower annual loss	May. 28	AN
PRISM BioLab, Co. Ltd. to Present E7386, Co-Developed Through Collaborative Research Between Eisai Co., Ltd., and Lenvatinib Mesylate	May. 22	CI
Jefferies Adjusts Eisai's Price Target to 3,600 Yen From 4,200 Yen, Keeps at Hold	May. 20	MT
US FDA clears first blood test for Alzheimer's detection	May. 16	RE
US FDA clears first blood test for Alzheimer's detection	May. 16	RE
Eisai, Biogen to Shift Some Lecanemab Ingredient Production to US Amid Tariff Concerns	May. 15	MT
Eisai Co., Ltd., 2025 Earnings Call, May 15, 2025	May. 15
Eisai Projects Leqembi® Revenue To Total JPY 76.5 Billion For FY 2025	May. 15	RE
Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2026	May. 14	CI
Trump's tariffs and threatened trade actions	May. 12	RE
Japan's Nikkei snaps 7-day winning streak as US tariff worries weigh	May. 07	RE
Japan's Nikkei heavy as US tariff woes counter China optimism	May. 06	RE
Eisai Co., Ltd. completed the acquisition of EcoNaviSta, Inc. from a group of shareholders.	May. 06	CI
Trump's tariffs and threatened trade actions	May. 05	RE
Biogen's results beat estimates on strength in rare disease drugs	May. 01	RE
Biogen's results beat estimates on strength in rare disease drugs	May. 01	RE
BioArctic AB?s Partner Eisai Announces That the Medicines and Healthcare Products Regulatory Agency Have Valued and Will Now Evaluate A Proposed Marketing Authorisation Variation for Monthly Leqemab Dosing in the United Kingdom	Apr. 30	CI

Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.

Employees

10,917

Sector

Pharmaceuticals

Calendar

Jul. 31 - Q1 2025 Earnings Release (Projected)

More about the company